Humanin inhibits the action of doxorubicin in breast cancer cells

MARIA FLORENCIA GOTTARDO; MARIELA MORENO AYALA; MERCEDES IMSEN; ANTONELA ASAD; MATIAS PIDRE; VICTOR ROMANOWSKI; MARIANELA CANDOLFI; ADRIANA SEILICOVICH

Mar del Plata

Congreso; Reunion Anual de la SAIC; 2016

SAIC

Humanin (HN) is a mitochondrial derived peptide with potent cytoprotective action in many cell types. It has been described that endogenous and exogenous HN can protect normal tissues against toxic effects of chemotherapy. However, the role of this peptide in tumor development is not well known. We have previously shown that HN is expressed in murine mammary carcinoma cells (4T1) and exerts antiapoptotic and mitogenic actions against various insults such as serum deprivation or TNF-α. The aim of this study was to investigate whether HN affects the sensitivity of tumor cells to chemotherapeutic agents. HN (10 µM) hampered the antiproliferative effect of doxorubicin (DOXO, 500 nM) on 4T1 cells in vitro (by ELISA BrdU; C=0.55±0.04; DOXO=0.34±0.02*, HN=0.52±0.02, DOXO+HN=0.53±0.01, *p